What happens when the world’s largest pharmaceutical market fundamentally changes the way it pays for medicines?
As US policy evolves around Most Favoured Nation pricing, the Inflation Reduction Act, CMS drug price negotiations and international reference pricing, the consequences could influence launch sequencing, commercial strategy and patient access around the world.
Season 3 of The Payer Exchange has a special US focus, bringing together complementary perspectives from specialty pharmacy, regional health plans, employer-sponsored healthcare and health policy. Combined, they build a broader picture of what’s happening on the ground in the US, where the market could be heading, and what that could mean for global healthcare systems.
Guests this series include:
🇺🇸 Jill Hanson, Centene Pharmacy Services – bringing a specialty pharmacy perspective from one of the largest Medicaid managed care organisations in the US, including how contracting could shift away from rebate maximisation and towards value-based agreements.
🇺🇸 Drake Reiter, Priority Health – exploring what happens next if pricing reforms begin to reshape the commercial market and challenge established thinking around value.
🇺🇸 Matt Harman, Employers Health – bringing the employer-sponsored health plan perspective, including the challenge of building financing and access models that make high-cost innovation sustainable for patients and purchasers.
🇺🇸 Ross Margulies, Manatt Health – examining the policy and legal landscape, and what MFN, the IRA, CMS drug price negotiations and international reference pricing could mean for global launch and market access strategy.
For anyone working in pricing, market access, HEOR or commercial strategy, these conversations offer direct insight into how different parts of the US healthcare system are responding to a period of significant change, and why manufacturers around the world are paying attention.
Four perspectives. One changing market. Global consequences.
Disclaimer: This podcast is for educational and informational purposes only, and is not intended as legal or policy advice. Views expressed by the speakers are personal opinions and should not be attributed to anyone else or any organization. No part of this presentation may be reproduced for commercial purposes without the express permission of Omar Ali, Verpora Limited.
